Eloxx Pharmaceuticals (NASDAQ:ELOX) Upgraded by Zacks Investment Research to Hold

Eloxx Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Eloxx Pharmaceuticals Upgraded by Zacks Investment Research on 10/19/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Eloxx Pharmaceuticals (NASDAQ:ELOX) Upgraded by Zacks Investment Research to Hold